am 251 has been researched along with Depressive Disorder, Major in 2 studies
AM 251: an analog of SR141716A; structure given in first source
AM-251 : A carbohydrazide obtained by formal condensation of the carboxy group of 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with the amino group of 1-aminopiperidine. An antagonist at the CB1 cannabinoid receptor.
Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Stress contributes to major depressive disorder (MDD) and chronic pain, which affect a significant portion of the global population, but researchers have not clearly determined how these conditions are initiated or amplified by stress." | 1.62 | mGluR5-Mediated eCB Signaling in the Nucleus Accumbens Controls Vulnerability to Depressive-Like Behaviors and Pain After Chronic Social Defeat Stress. ( Han, J; Huang, M; Luo, L; Ma, X; Shi, H; Su, C; Wang, A; Wang, H; Wang, W; Wu, K; Xu, T; Xu, X; Yuan, T, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, X | 1 |
| Wu, K | 1 |
| Ma, X | 1 |
| Wang, W | 1 |
| Wang, H | 1 |
| Huang, M | 1 |
| Luo, L | 1 |
| Su, C | 1 |
| Yuan, T | 1 |
| Shi, H | 1 |
| Han, J | 1 |
| Wang, A | 1 |
| Xu, T | 1 |
| Hill, MN | 1 |
| Ho, WS | 1 |
| Sinopoli, KJ | 1 |
| Viau, V | 1 |
| Hillard, CJ | 1 |
| Gorzalka, BB | 1 |
2 other studies available for am 251 and Depressive Disorder, Major
| Article | Year |
|---|---|
mGluR5-Mediated eCB Signaling in the Nucleus Accumbens Controls Vulnerability to Depressive-Like Behaviors and Pain After Chronic Social Defeat Stress.
Topics: Animals; Cannabinoid Receptor Antagonists; Chronic Disease; Depressive Disorder, Major; Endocannabin | 2021 |
Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis.
Topics: Animals; Antidepressive Agents, Tricyclic; Cannabinoid Receptor Modulators; Cortisone; Depressive Di | 2006 |